Wells Fargo upgrades Blueprint Medicines to Overweight, raises target to $82

As previously reported, Wells Fargo analyst Derek Archila upgraded Blueprint Medicines to Overweight from Equal Weight with a price target of $82, up from $55. The firm is taking a swing ahead of Q2 after rerunning our Ayvakit survey. The trends continue to look good, and based on the number of incremental ISM patients docs have treated, Wells thinks revenues should top consensus estimates in Q2.